Document Detail

B-cell-depleting therapy in systemic lupus erythematosus.
MedLine Citation:
PMID:  22444096     Owner:  NLM     Status:  MEDLINE    
The emergence of a new class of agents (B-cell-depleting therapies) has opened a new era in the therapeutic approach to systemic lupus erythematosus, with belimumab being the first drug licensed for use in systemic lupus erythematosus in more than 50 years. Four agents deserve specific mention: rituximab, ocrelizumab, epratuzumab, and belimumab. Controlled trials have shown negative results for rituximab, promising results for epratuzumab, and positive results for belimumab. Despite these negative results, rituximab is the most-used agent in patients who do not respond or are intolerant to standard therapy and those with life-threatening presentations. B-cell-depleting agents should not be used in patients with mild disease and should be tailored according to individual patient characteristics, including ethnicity, organ involvement, and the immunological profile. Forthcoming studies of B-cell-directed strategies, particularly data from investigations of off-label rituximab use and postmarketing studies of belimumab, will provide new insights into the utility of these treatments in the routine management of patients with systemic lupus erythematosus.
Manuel Ramos-Casals; Iñaki Sanz; Xavier Bosch; John H Stone; Munther A Khamashta
Related Documents :
24055246 - Validation of a european spanish-version of the university of california performance sk...
16271496 - Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms...
8318176 - Effects of zidovudine in 30 patients with mild to end-stage aids dementia complex.
19595846 - Undertreatment of patients with alzheimer's disease in an elderly united states populat...
18717916 - Patients' understanding of the reasons for starting and discontinuing inhaled corticost...
23866846 - Viral load dynamics in adult patients with a(h1n1)pdm09 influenza.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  125     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-26     Completed Date:  2012-05-14     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  327-36     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
B-Lymphocytes / immunology*
Lupus Erythematosus, Systemic / drug therapy*,  immunology
Randomized Controlled Trials as Topic
Grant Support
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/epratuzumab; 0/ocrelizumab; 0/rituximab; 73B0K5S26A/belimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of fish oil on ruminal biohydrogenation of C18 unsaturated fatty acids in steers fed grass or...
Next Document:  Digitalis toxicity: a fading but crucial complication to recognize.